TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES

Authors:
  • JKJean-François Korobelnik
    Jean-François Korobelnik
  • RDRobert Devenyi
    Robert Devenyi
  • CFCarsten Framme
    Carsten Framme
  • JGJohn Galic
    John Galic
  • EHEdward Herbert
    Edward Herbert
  • HHHans Hoerauf
    Hans Hoerauf
  • PLPaolo Lanzetta
    Paolo Lanzetta
  • SMStephan Michels
    Stephan Michels
  • PMPaul Mitchell
    Paul Mitchell
  • CRCarl Regillo
    Carl Regillo
Top Cited Papers
Publisher website
Google Scholar
Abstract
A review of treat-and-extend regimens (TERs) with intravitreal anti–vascular endothelial growth factor agents in retinal diseases. There is a lack of consensus on the definition and optimal application of TER in clinical practice. This article describes the supporting evidence and subsequent development of a generic algorithm for TER dosing with anti–vascular endothelial growth factor agents, considering factors such as criteria for extension. A TER algorithm was developed; TER is defined as an individualized proactive dosing regimen usually initiated by monthly injections until a maximal clinical response is observed (frequently determined by optical coherence tomography), followed by increasing intervals between injections (and evaluations) depending on disease activity. The TER regimen has emerged as an effective approach to tailoring the dosing regimen and for reducing treatment burden (visits and injections) compared with fixed monthly dosing or monthly visits with optical coherence tomography–guided regimens (as-needed or pro re nata). It is also considered a suitable approach in many retinal diseases managed with intravitreal anti–vascular endothelial growth factor therapy, given that all eyes differ in the need for repeat injections. It is hoped that this practical review and TER algorithm will be of benefit to health care professionals interested in the management of retinal diseases.

This publication has 49 references indexed in Scilit: